Doxepin vs Nandrolone
FDA Approved vs FDA Approved
avoid Mechanism-based · 70% Both Doxepin and Nandrolone carry cardiovascular risk. Combined cardiotoxic load increases risk of cardiac events. Regular cardiac monitoring recommended.
Molecular Data
Doxepin Nandrolone
Weight 279.38 Da 274.40 Da (base)
Half-life ~15 hours ~6-12 days (decanoate)
Type Tricyclic dibenzoxepin derivative (C19H21NO) 19-nortestosterone steroid (C18H26O2)
Key Benefits
Doxepin
01 FDA-approved specifically for sleep maintenance insomnia at ultra-low doses (3-6 mg as Silenor)
02 Highly selective H1 antihistamine at low doses, avoiding the side effects of traditional tricyclic antidepressants
03 Non-habit-forming with no dependence, tolerance, or abuse potential
04 No rebound insomnia upon discontinuation, unlike benzodiazepines and Z-drugs
05 Particularly effective for maintaining sleep in the latter half of the night, when many other sleep aids have worn off
06 Extremely well-tolerated side effect profile at ultra-low doses
Nandrolone
01 Significant increases in lean muscle mass with a favorable anabolic-to-androgenic ratio
02 Enhanced collagen synthesis and joint lubrication, reducing joint pain and improving connective tissue integrity
03 Increased bone mineral density through direct osteoblast stimulation
04 Improved nitrogen retention and protein synthesis for accelerated recovery
05 Stimulation of erythropoietin production, increasing red blood cell mass and oxygen delivery
06 Lower androgenic side effects (hair loss, acne, prostate enlargement) compared to testosterone
07 Clinically demonstrated efficacy in treating anemia of chronic renal failure
08 Potential neuroprotective properties observed in preclinical research
Dosing Protocols
Doxepin
3-6 mg at bedtime (sleep) / Once daily at bedtime
Nandrolone
100-200 mg/week (therapeutic) / 1x per week (decanoate) or 2-3x per week (NPP)
TRT Adjunct - Joint Support 50-100 mg/week 1x per week (decanoate)
Therapeutic - Anemia / Wasting 100-200 mg/week 1x per week (decanoate)
Performance Enhancement - Moderate 200-400 mg/week 1x per week (decanoate) or split into 2 injections
NPP Protocol - Shorter Cycle 200-350 mg/week Every other day or 3x per week
Side Effects
Doxepin
Morning drowsiness or grogginess (more common at the 6 mg dose; uncommon at 3 mg)
Dry mouth (mild at ultra-low doses, much less than at antidepressant doses)
Nausea
Upper respiratory tract infection (observed in clinical trials at rates similar to placebo)
Nandrolone
Suppression of natural testosterone production (profoundly suppressive, more so than testosterone alone)
Water retention and bloating (less than testosterone at equianabolic doses)
Erectile dysfunction and reduced libido without concurrent testosterone ('deca dick')
Increased appetite and weight gain
Mild acne and oily skin (less pronounced than testosterone)
Elevated hematocrit and hemoglobin (erythrocytosis)
Injection site pain or discomfort
Mild mood changes (some users report increased emotional sensitivity)
Contraindications
Known hypersensitivity to doxepin or other dibenzoxepines
Concurrent use of MAOIs or use within 14 days of MAOI discontinuation
Untreated narrow-angle glaucoma
Severe urinary retention
Severe hepatic impairment (doxepin is extensively hepatically metabolized)
Prostate cancer (active or history of hormone-sensitive prostate cancer)
Breast cancer in males or females
Pregnancy or potential for pregnancy (Category X - causes virilization of female fetus)
Nephrosis or the nephrotic phase of nephritis
Severe hepatic impairment
Hypercalcemia
Known hypersensitivity to nandrolone or any formulation components
Polycythemia (hematocrit above 54% at baseline)
Uncontrolled heart failure or severe cardiovascular disease
Research Evidence
Doxepin Nandrolone
Status FDA Approved FDA Approved
References 4 studies 5 studies
Latest — April 2005
FDA Approved Yes Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.